Opioid and benzodiazepine requirements in neonatal and pediatric patients undergoing venoarterial ECMO: insights from a predominantly cardiac cohort - Report - MDSpire
Advertisement
Sedation and Analgesic Use of Opioids and Benzodiazepines in Neonates and Children on Venoarterial ECMO: Findings from a Primarily Cardiac Patient Group
Sedation and Analgesic Use of Opioids and Benzodiazepines in Neonates and Children on Venoarterial ECMO
Overview
This study evaluates sedation and analgesia management in neonates and children on venoarterial ECMO, highlighting significant cumulative opioid and benzodiazepine exposures.
Background
Sedation and analgesia are vital for neonates and pediatric patients on ECMO, as these patients often require deep sedation to prevent complications. The pharmacokinetics of sedatives can be altered in this population, necessitating careful management to avoid oversedation and withdrawal.
Data Highlights
Measure
Median (mg/kg)
Cumulative Opioid Exposure
7.33
Cumulative Benzodiazepine Exposure
15.75
Key Findings
All patients received opioids, and 96.3% received benzodiazepines.
Median cumulative opioid exposure was 7.33 mg/kg.
Median cumulative benzodiazepine exposure was 15.75 mg/kg.
Prolonged ICU length of stay and ECMO duration were linked to higher cumulative opioid exposure.
Clinical Implications
Clinicians should be aware of the significant opioid and benzodiazepine exposure in neonates and children on ECMO.
Conclusion
The findings highlight the need for careful management of sedative exposure in pediatric ECMO patients.
by Somayah A. Alsuhaibani, Ashjan F. Alghanem, Ibrahim A. Alredaini, Shaimaa Alsulami, Luluah A. AlTukhaifi, Reem M. Beheri, Mashael AlFaifi, Renad A. Alshuraim, Lama Alfehaid, Khalid Al Sulaiman
